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Mycoplasma pneumoniae infection can cause pneu-
monia, particularly in children. Global increase in 
macrolide-resistant M. pneumoniae is of concern due 
to limited therapeutic options. We describe the detec-
tion of macrolide resistance-conferring mutations in 
9.3% of 43 clinical specimens where M. pneumoniae 
was detected in England and Wales from September 
2014-September 2015. This study aims to impact by 
highlighting the presence of macrolide resistance in 
M. pneumoniae positive patients, promoting increased 
clinical vigilance.
Here we report the detection of mutations associated 
with macrolide resistance in M. pneumoniae-posi-
tive specimens from four patients with pneumonia in 
Englandin the periodSeptember 2014 to September 
2015. Prior to 2014, in the United Kingdom seven 
cases of macrolide-resistant M. pneumoniae infections 
were reported between 2008 and 2011, mainly from 
Scotland [1,2].
Macrolide resistance determination
The Bacteriology Reference Department, Public Health 
England (PHE), London, receives specimens from 
England and Wales for M. pneumoniae testing and 
confirmatory testing. Here we detected M. pneumo-
niae by qPCR in 60 clinical specimens from 60 patients 
(Cambridge, Leeds, London, Manchester, Nottingham 
and Oxford) that were submitted to PHE between 1 
September 2014 and 1 September 2015. DNA extrac-
tions from specimens, where M. pneumoniae was 
detected, were screened for point mutations known to 
confer macrolide resistance. Mutations in domain V of 
the 23S rRNA were detected by a modified version of 
the method described by Li et al., 2009 [3], wherein the 
entire region of interest is amplified and sequenced as 
one product. Primers used were as follows: forward 
primer 5’-ATCTCTTGACTGTCTCGGC-3’ and reverse primer 
5’-TACAACTGGAGCATAAGAGGTG-3’.
Of the 60 specimens, 17 (28.3%; 95% confidence 
interval (CI): 18.4--40.8) contained insufficient DNA 
to determine macrolide resistance-conferring muta-
tions. Of the remaining 43 specimens mutations in 
the 23S rRNA known to confer macrolide resistance 
were found in four (9.3%; 95% CI: 3.1–22.2). Of these 
43 specimens, 32 were from a single city in England, 
Leeds, and a single specimen among these was posi-
tive for the mutation, 3.1% (95% CI: 0.01–17.1). The 
cases identified with point mutations known to confer 
macrolide-resistant M. pneumoniae were in two women 
and two men, respectively, aged > 15 to <65 years old. 
Three were hospitalised with pneumonia (Table) with 
no known connection between patients.
Interestingly, two of the macrolide-resistant cases 
were patients that had recently arrived from the United 
States (exact timeline unknown); of which one had 
received clarithromycin whilst undergoing treatment 
in the UK. The origins of the infecting M. pneumoniae 
strains in these two cases may have been external to 
England and Wales. The other two cases were from 
separate cities in England. All macrolide resistance-
conferring mutations were A2058G (Escherichia coli 
numbering) point mutation in the 23S rRNA.
Background
Mycoplasma pneumoniae can be isolated from patients 
with lower respiratory tract infection, including pneu-
monia, and has also been associated with prolonged 
persistent cough and exacerbation of asthma [4]. M. 
pneumoniae infections may manifest infrequently as 
extra-pulmonary sequelae after the onset of or even 
in the absence of respiratory illness [5]; including 
encephalitis [6], dermatological manifestations such 
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as Stevens-Johnson syndrome [7], and haemolytic 
anaemia [8]. Asymptomatic carriage of M. pneumo-
niae has been documented in nasopharyngeal swabs 
at low levels in England, e.g. at 0.25% based on PCR 
in a 2001 carriage study [9], however, a study from 
the Netherlands reported a much higher carriage rate 
(21.2%) [10]. In England and Wales, M. pneumoniae 
infection can be found in all age groups, with a higher 
prevalence in children of school age [9]. In England 
and Wales, seasonal peaks of infection are detected 
from December to February each year with epidemics 
at approximately four-yearly intervals, lasting 12 to 15 
months [9]. A large increase in reported M. pneumo-
niae cases was documented in several European coun-
tries, including England and Wales, in 2011 [11]. 
Discussion
In the past 15 years, a significant increase in macrolide-
resistant M. pneumoniae has been reported globally, 
of increasing concern and importance to the interna-
tional community [12]. In Asia, resistance rates of over 
90% have been reported [13], particularly in China, 
whereas in Europe and North America resistance rates 
of up to 25% have been documented [14,15]. Macrolide-
resistant strains of M. pneumoniae have not been doc-
umented to show cross-resistance to other classes of 
antibiotics i.e. tetracyclines and fluoroquinolones [16].
 
Prior to 2014, in the United Kingdom, seven cases of 
macrolide-resistant M. pneumoniae infections were 
reported between 2008 and 2011, one case in England 
and Wales and six cases in Scotland [1,2]. This is the 
second report of macrolide-resistant M. pneumoniae 
strains detected in England and Wales, with one case 
previously documented for a single patient specimen 
from 2008 [1]. Macrolide resistance in M. pneumoniae 
has been reported in Scotland at 19% (6/32) [2], con-
siderably higher than the 9.3% documented here. This 
may reflect low sample numbers or sampling differ-
ences and it is important to note that the specimens 
examined for macrolide resistance in Scotland were 
from patients in whom macrolide resistance was con-
sidered most likely based on their clinical presenta-
tion or history, being one of the following: repeated 
specimen positive, remaining symptomatic following 
antibiotic treatment, admitted to critical care or having 
an underlying condition. 
In this study a high number of samples were from a 
single city in England and a local epidemic cannot 
be excluded. There is no requirement for referral of 
M. pneumoniae-positive specimens to the reference 
laboratory in England and Wales. Systematic testing 
and referral of positive specimens does not occur. 
Therefore regional comparison was not possible. 
Nonetheless, the focus of this article was to highlight 
macrolide resistance rather than a specific regional 
cluster analysis.
Macrolides are currently recommended as the first-
line treatment for M. pneumoniae infection in the UK 
[17]. The 2011 British Thoracic Society guidelines for 
the management of community acquired pneumonia in 
children and adults suggest empirical macrolide treat-
ment at any age if there is no response to first-line beta-
lactam antibiotics or in the case of very severe disease 
[17,18]. Tetracyclines (minocycline and doxycycline) 
and fluoroquinolones (levofloxacin and moxifloxacin) 
can be used to treat M. pneumoniae infections as an 
alternative to macrolides when clinically relevant [19], 
however, their use in children is limited due to effects 
on bone toxicity and cartilage development, respec-
tively [20,21].
We did not isolate M. pneumoniae by culture from those 
specimens wherein M. pneumoniae was detected by 
PCR and therefore we were not able to confirm pheno-
typic macrolide resistance. However, point mutations 
within the 23SrRNA gene in clinical specimens and 
isolates, including the A2058G mutation, have previ-
ously been shown to confer resistance [16]. Acquisition 
of resistance has been documented in patients receiv-
ing macrolides and resistance may develop as a con-
sequence of antibiotic selective pressure [22]. This is 
supported by the highest macrolide resistance rates 
being reported in countries with extensive macrolide 
use [15]. Increased vigilance pertaining to macrolide-
resistant M. pneumoniae in the UK is recommended.
Case Age group (years) Sample type Pneumonia Hospitalised Macrolide before sampling
1 45–65 TS Yes Yes Unknown
2 15–25 BAL Yes Yes Yes
3 45–65 BAL Yes Yes Unknown; Antibiotics class unknown administered before admission
4 15–25 TS Yes Unknown Unknown
BAL: bronchoalveolar lavage; TS: throat swab.
Table
Details of patients with macrolide-resistant Mycoplasma pneumoniae-positive clinical specimens, England and Wales, 
September 2014–September 2015 (n=4)
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